Trilogy Capital Inc. Sells 157 Shares of DexCom, Inc. (NASDAQ:DXCM)

Trilogy Capital Inc. cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,710 shares of the medical device company’s stock after selling 157 shares during the period. Trilogy Capital Inc.’s holdings in DexCom were worth $522,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter valued at $25,000. Riverview Trust Co boosted its holdings in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter valued at $38,000. RPg Family Wealth Advisory LLC bought a new position in DexCom in the 3rd quarter valued at $57,000. Finally, Covestor Ltd boosted its holdings in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock worth $3,628,069 over the last 90 days. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

DXCM stock opened at $88.32 on Friday. The firm’s 50-day moving average price is $81.35 and its two-hundred day moving average price is $75.69. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market capitalization of $34.50 billion, a price-to-earnings ratio of 52.89, a PEG ratio of 2.23 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a report on Monday. Oppenheimer dropped their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.